Id |
Subject |
Object |
Predicate |
Lexical cue |
T103 |
0-135 |
Sentence |
denotes |
Since monotherapy is not recommended in treating HIV, HCQ has also been tested in synergy with other drugs commonly used to manage HIV. |
T104 |
136-385 |
Sentence |
denotes |
In this regard, 400 mg/day of HCQ in a combination regimen with 1000 mg/day hydroxyurea and 250–400 mg/day didanosine (dosed per body weight) was administered for 48 weeks to 22 asymptomatic HIV-1 infected patients naïve to antiretroviral treatment. |
T105 |
386-428 |
Sentence |
denotes |
Only 16 out of 22 patients were evaluable. |
T106 |
429-552 |
Sentence |
denotes |
These 16 subjects, at the 12th week, showed a significant reduction in viral load which was maintained until the 48th week. |
T107 |
553-680 |
Sentence |
denotes |
Furthermore, at week 12, an increase in CD4+ percentage was also shown, and this improvement was kept until the 48th week [19]. |
T108 |
681-846 |
Sentence |
denotes |
To evaluate the long-term efficacy and safety of HCQ, hydroxyurea, and didanosine combination, they were also tested on 17 HIV-infected naïve patients for 144 weeks. |
T109 |
847-939 |
Sentence |
denotes |
All subjects received 200 mg HCQ, 500 mg hydroxyurea, and 125–200 mg didanosine twice daily. |
T110 |
940-1026 |
Sentence |
denotes |
Of the 17 patients who started treatment, 14 remained until the end of the 144th week. |
T111 |
1027-1284 |
Sentence |
denotes |
After 114 weeks, viral load was reduced by 1.6 Log10 copies/mL under baseline (p < 0.001), eight patients (47%) had an unnoticeable viral load (< 400 copies/mL), and two patients (12%) had a measurable viral load, but resistance mutations were not detected. |
T112 |
1285-1525 |
Sentence |
denotes |
Four patients (24%) had both detectable viral load and resistance mutation: one with both 62V and 65R and three with both 74V and 184V mutations; the latter three were assessed as didanosine resistant, while no resistance was found for HCQ. |
T113 |
1526-1610 |
Sentence |
denotes |
However, in all cases, the viral load remained below the baseline at the 144th week. |
T114 |
1611-1732 |
Sentence |
denotes |
The CD4+ cell count had increased significantly, while the percentage of CD8 cells was reduced up to the 144th week [20]. |
T115 |
1733-1965 |
Sentence |
denotes |
This HCQ noticeable impact on immune activation, thereby increasing CD4+ T cells, was also demonstrated in a prospective study conducted on 20 HIV-infected immunologic no responders treated with standard antiretroviral therapy [23]. |
T116 |
1966-2130 |
Sentence |
denotes |
These results suggested that the combination of HCQ, hydroxyurea, and didanosine could be a valid alternative to the highly active commercial HAART in HIV-patients. |
T117 |
2131-2269 |
Sentence |
denotes |
Nonetheless, these latter studies have some limitations, such as the small number of subjects included and the absence of a control group. |
T118 |
2270-2419 |
Sentence |
denotes |
Therefore, it is not possible to determine the contribution made by HCQ to the overall decrease in viral load obtained from the combination of drugs. |
T119 |
2420-2652 |
Sentence |
denotes |
Anyway, the potential anti-HIV efficacy of HCQ, when added to existing treatment with an antiretroviral regimen, was also confirmed by a case report about a patient with HLA-B27-associated spondyloarthropathy and HIV infection [43]. |